This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
Should You Buy Ur Energy (URG) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
URGNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, Envista (NVST)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
NVSTPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
OPRX Delivers Solid Q1 Earnings: But Can It Sustain the Momentum?
by Indrajit Bandyopadhyay
OptimizeRx posts 11% Q1 growth and rising EBITDA, but long-term momentum hinges on scaling subscriptions and margin mix gains.
OPRXNegative Net Change HSTMNegative Net Change HCATNegative Net Change
medical medical-devices
Can ISRG's Strong Q2 Procedure Volume Translate Into Durable EPS Upside?
by Indrajit Bandyopadhyay
ISRG's Q2 procedure growth hits 17%, but continuation of EPS growth hinges on easing margin pressure from FX and da Vinci 5 adoption.
ISRGPositive Net Change GMEDPositive Net Change ZBHNegative Net Change
medical medical-devices
HOLX vs. EXAS: Which Cancer Diagnostics Stock Should You Retain Now?
by Moumi Mondal
EXAS gains edge over HOLX as rising Cologuard adoption, new launches and bullish EPS trends boost investor appeal.
HOLXPositive Net Change EXASPositive Net Change
medical medical-devices
Can Sustained Strength in Water Drive ECL Stock Before Q2 Earnings?
by Zacks Equity Research
Ecolab rides momentum in Global Water and Pest Elimination, but macroeconomic headwinds may test its second-quarter 2025 earnings strength.
ECLNegative Net Change ESINegative Net Change BCPCNegative Net Change HWKNNegative Net Change
earnings medical medical-devices
Veeva's Vault Vision: Can It Thrive After Parting With Salesforce?
by Harshit Gupta
VEEV stock climbs 36% YTD as it accelerates its shift off Salesforce, betting on Vault to power future growth in life sciences.
CRMNegative Net Change VEEVNegative Net Change IQVNegative Net Change
medical medical-devices
Revvity Q2 Preview: Can Strong Segments Deliver an Earnings Beat?
by Zacks Equity Research
RVTY is likely to see another earnings beat as Diagnostics momentum and Signals Software growth offset tariff headwinds.
CAHPositive Net Change CORPositive Net Change WGSNegative Net Change RVTYPositive Net Change
medical medical-devices
Labcorp Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market
by Zacks Equity Research
LH tops Q2 estimates with double-digit EPS growth, margin gains and a raised 2025 outlook, lifting shares pre-market.
LHPositive Net Change ISRGPositive Net Change RMDPositive Net Change VEEVNegative Net Change
earnings medical medical-devices
WST Stock Rises on Q2 Earnings Beat, EPS View Up on Tariff & FX Benefit
by Zacks Equity Research
West Pharmaceutical's second-quarter top line continues to benefit from revenue growth in its Proprietary Products segment.
ALGNPositive Net Change CAHPositive Net Change CORPositive Net Change WSTNo Net Change
earnings medical medical-devices
Will DXCM Q2 Earnings Reflect U.S. Coverage Expansion & Stelo Impact?
by Zacks Equity Research
DexCom Q2 results are likely to reflect strong growth on the back of coverage by two large PBMs and Stelo traction, driving momentum and market expansion in 2025.
CAHPositive Net Change DXCMNegative Net Change CORPositive Net Change WGSNegative Net Change
medical medical-devices
Coherent (COHR) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
COHRNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Preferred Bank (PFBC)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
PFBCNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Hologic's International Momentum Takes Shape: Will Execution Pay Off?
by Moumi Mondal
HOLX is leaning into international growth with Surgical division strength and untapped demand driving momentum abroad.
ABTPositive Net Change BDXNegative Net Change HOLXPositive Net Change
medical medical-devices
Company News for Jul 24, 2025
by Zacks Equity Research
Companies In The News Are: T, TMO, GD, BSX.
GDNegative Net Change TPositive Net Change BSXPositive Net Change TMONegative Net Change
aerospace medical-devices tech-stocks
New Strong Sell Stocks for July 24th
by Zacks Equity Research
COMP, EKTAY and BLCO have been added to the Zacks Rank #5 (Strong Sell) List on July 24, 2025.
EKTAYNegative Net Change COMPNegative Net Change BLCONegative Net Change
computers medical medical-devices
CVS Q2 Estimates Dip: Is the Stock Still a Buy Ahead of Q2 Earnings?
by Urmimala Biswas
Earnings estimates for CVS dip ahead of Q2 results, but turnaround efforts in Aetna and PBM strength may offset pressure.
UNHNegative Net Change CVSPositive Net Change HLFNegative Net Change
earnings-estimates-revisions earnings-outlook earnings-preview earnings-report earnings-streak earnings-surprise healthcare medical medical-devices retail
Veeva vs. Salesforce: Which Life Sciences CRM Stock Is the Better Buy?
by Harshit Gupta
VEEV's split from Salesforce sets the stage for a high-stakes CRM showdown as both firms double down on life sciences innovation.
CRMNegative Net Change VEEVNegative Net Change
artificial-intelligence internet medical medical-devices
Boston Scientific Beats on Q2 Earnings, Raises 2025 View, Stock Up
by Zacks Equity Research
BSX beats Q2 estimates, raises full-year outlook as Cardiovascular sales surge and global revenues climb 22.8%.
BSXPositive Net Change RMDPositive Net Change CORPositive Net Change VEEVNegative Net Change
earnings medical medical-devices
Arista Networks (ANET) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
ANETNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, Figs (FIGS)'s Technical Outlook is Bright
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
FIGSNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, GXO Logistics (GXO)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
GXONegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Anywhere Real Estate (HOUS) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
HOUSNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, Synovus Financial (SNV)'s Technical Outlook is Bright
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
SNVNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Stock Market News for Jul 23, 2025
by Zacks Equity Research
Wall Street closed mixed on Tuesday as market participants were busy weighing uncertainties related to tariff rates and trade policies.
PHMPositive Net Change DHIPositive Net Change IQVNegative Net Change
home-builder medical-devices